4//SEC Filing
Hudson Thomas J 4
Accession 0001415889-23-002940
CIK 0001551152other
Filed
Feb 20, 7:00 PM ET
Accepted
Feb 21, 6:07 PM ET
Size
13.9 KB
Accession
0001415889-23-002940
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Hudson Thomas J
SVP, R&D and CSO
Transactions
- Award
Common Stock, $0.01 par value
2023-02-16+40,640→ 86,868 total - Award
Common Stock, $0.01 par value
2023-02-16+5,350→ 109,251 total - Award
Common Stock, $0.01 par value
2023-02-16+7,552→ 103,901 total - Award
Common Stock, $0.01 par value
2023-02-16+9,481→ 96,349 total - Award
Option (Right to Buy)
2023-02-16+20,256→ 20,256 totalExercise: $149.62From: 2024-02-16Exp: 2033-02-15→ Common Stock (20,256 underlying)
Footnotes (5)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
- [F3]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
- [F4]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,752 on February 16, 2024, 6,752 on February 16, 2025, and 6,752 on February 16, 2026.
Documents
Issuer
AbbVie Inc.
CIK 0001551152
Entity typeother
Related Parties
1- filerCIK 0001781947
Filing Metadata
- Form type
- 4
- Filed
- Feb 20, 7:00 PM ET
- Accepted
- Feb 21, 6:07 PM ET
- Size
- 13.9 KB